CTLA4 and colorectal cancer: Based on the results from the PICC and NICHE-2 studies, the CSCO Guidelines for Diagnosis and Treatment of Colorectal Cancer (2023) recommends the use of ICIs (PD-1 ± CTLA-4) for dMMR/MSI-H patients at cT4b, followed by radical surgery.